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Abstract: A significant number of meta-analyses reporting data on the diagnostic performance of
positron emission tomography (PET) in prostate cancer (PCa) is currently available in the literature.
In particular, different PET radiopharmaceuticals were used for this purpose. The aim of this review
is to summarize information retrieved by published meta-analyses on this topic. The first step
included a systematic search of the literature (last search date: June 2020), screening two databases
(PubMed/MEDLINE and Cochrane Library). This combination of key words was used: (A) “PET”
OR “positron emission tomography” AND (B) “prostate” OR “prostatic” AND (C) meta-analysis.
Only meta-analyses on Positron Emission Tomography/Computed Tomography (PET/CT) or Positron
Emission Tomography/Magnetic Resonance (PET/MR) in PCa were selected. We have summarized
the diagnostic performance of PET imaging in PCa, taking into account 39 meta-analyses published
in the literature. Evidence-based data showed the good diagnostic performance of PET/CT with
several radiopharmaceuticals, including prostate-specific membrane antigen (PSMA)-targeted agents,
radiolabeled choline, fluciclovine, and fluoride in restaging and staging settings. Less evidence-based
data were available for PET/MR with different radiotracers. More prospective multicentric studies
and cost-effectiveness analyses are warranted.
Keywords: PET; choline; PSMA; prostate; meta-analysis; evidence-based; nuclear medicine; imaging
1. Introduction
Prostate cancer (PCa) is the most frequent type of cancer in men worldwide. PCa patients may
be treated with radical prostatectomy or radiotherapy as primary treatments, but they may develop
disease recurrence [1].
In the clinical setting of PCa screening, the use of a prostatic-specific antigen (PSA) has led to
earlier diagnosis. The first sign of disease recurrence is represented by increasing levels of PSA,
known as biochemical recurrence (BR). In early recurrence, potentially curative salvage therapies,
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such as secondary lymphadenectomy or targeted radiotherapy can be adopted, but both require the
disease to be localized [1].
In patients with intermediate- to high-risk PCa and those with BR-PCa, current guidelines
recommend disease staging and restaging using conventional imaging, including computed
tomography (CT) and magnetic resonance (MR), as well as whole-body bone scintigraphy [1]. In this
clinical scenario, morphologic imaging, such as CT, firstly offered a whole-body diagnostic tool both
in a staging and restaging setting. At the same time, MR offered a useful tool for the diagnosis of
loco-regional disease. About functional imaging, bone scanning with radiolabeled diphosphonates has
been widely used for the detection and monitoring of PCa bone metastases: the radiopharmaceutical
mimics phosphate and adsorbs to areas of active bone formation, particularly around metastases where
osteoblastic activity is prominent.
Unfortunately, anatomical imaging techniques depend solely on morphological features for
identifying metastatic disease: as small lesions are frequently missed by morphological imaging
techniques, PCa disease can be understaged by using CT or MR. Currently, the general diagnostic
performance of morphologic imaging for detecting lymph nodal metastases of PCa remains limited:
using histopathology as reference standard, CT and MR showed a sensitivity <50% [1].
About bone scintigraphy, this method may detect lesions not seen by CT in some cases, but it
lacks adequate specificity as benign lesions causing increased osteoblastic activity can be mistaken for
PCa metastases. In detecting bone metastases at initial diagnosis of PCa, bone scintigraphy presents a
relatively low diagnostic yield of 3.5% with PSA ≤ 10 ng/mL, 6.9% with PSA between 10 and 20 ng/mL,
and 41.8% with PSA > 20 ng/mL [1]. Lastly, a bone scan only examines the bones and will ignore
lymphatic or visceral metastases of PCa [1].
Positron emission tomography (PET) combined with CT (PET/CT) or MR (PET/MR) using several
radiopharmaceuticals are emerged as new-generation imaging methods to allow a more accurate and
precise staging and restaging of PCa. These whole-body imaging methods combining functional with
anatomical information provide an increased diagnostic accuracy in detecting PCa lesions compared
to CT, MR, and bone scintigraphy [1].
Different radiotracers for PET imaging have been proposed in recent years, such as
radiolabeled choline (Cho) [2–20], prostate-specific membrane antigen (PSMA)-targeted
agents [21–32], 18F-fluciclovine (FACBC) [8,32–36], 18F-fluoride (NaF) [4,37], 11C-acetate [11,14,38],
and 18F-fluorodeoxyglucose (18F-FDG) [11,14]. Moreover, different radioisotopes have been proposed
to label some of these radiopharmaceuticals, such as to label Cho (e.g., 18F, 11C) and PSMA-targeted
agents (e.g., 68Ga, 18F, 64Cu). Each tracer has different uptake features: radiolabeled Cho and acetate are
markers of the cell membrane synthesis; PSMA is a membrane antigen overexpressed in the majority
of PCa cells, and it is a target for a variety of urea-derived agents; fluciclovine uptake is related to
functional activity of amino acid transporters; fluoride and 18F-FDG mark the metabolism of bone
matrix and cell glucose, respectively [1]. While PET imaging is usually performed with coregistered
CT, hybrid PET/MR was also recently proposed for the management of PCa [5].
To date, several meta-analyses have reported evidence-based data about the diagnostic
performance of PET imaging in PCa with different radiotracers [2–40]. The aim of this review
is to summarize information retrieved by published meta-analyses on this topic.
2. Materials and Methods
A comprehensive computer literature search of PubMed/MEDLINE and Cochrane library databases
was conducted to find recent published meta-analyses on the diagnostic performance of PET imaging
for the diagnosis of PCa.
A search algorithm based on the combination of the following terms was used: (A) “PET” OR
“positron emission tomography” AND (B) “prostate” OR “prostatic” AND (C) meta-analysis. The literature
search was updated until June 30th, 2020. No language restriction was used. Recent meta-analyses
published in the last ten years and investigating the diagnostic performance of PET imaging in PCa were
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considered eligible for inclusion. Titles and abstracts of the retrieved articles were reviewed, applying
the inclusion criteria mentioned above.
For each selected meta-analysis, information was collected about basic study characteristics
(authors, year of publication, number of original articles included, number of patients included),
and diagnostic performance measures. The main findings of the selected meta-analyses were
briefly described.
3. Results
Performing a systematic search of the literature (last search date: June 2020) screening two databases
(PubMed/MEDLINE and Cochrane Library), 39 meta-analyses were selected [2–40], most of them
related to PET/CT, and only two focused on PET/MR [5,40]. Main characteristics of the meta-analyses
about PET/CT with different tracers are presented in Tables 1–5. The main findings of the selected
evidence-based articles are summarized here below taking into account the different types of PET
radiopharmaceuticals used for PCa evaluation.
3.1. Radiolabeled Choline (Cho) PET/CT
In the first published meta-analyses [19,20], radiolabeled Cho PET and PET/CT showed high
sensitivity and specificity for the detection of locoregional and distant metastases in PCa patients with
a recurrence of disease (BR-PCa) but low sensitivity and high specificity in the detection of lymph node
metastases prior to surgery in intermediate- and high-risk PCa patients. According to the meta-analysis
of Evangelista et al. [19], radiolabeled Cho PET and PET/CT provided a pooled sensitivity of 85.6% and
a pooled specificity of 92.6% for all sites of disease (prostatic fossa, lymph nodes, and bone) in BR-PCa
patients. Conversely, pooled sensitivity and specificity of these methods in detecting PCa lymph nodal
metastases prior to surgery were 49.2% and 95%, respectively [20].
These findings were confirmed by Umbehr et al. [18]: in staging PCa patients, on a per-patient
basis, radiolabeled Cho PET or PET/CT showed pooled sensitivity and specificity of 84% and 79%,
respectively; on a per-lesion basis, these values were 66% and 92%, respectively. In restaging PCa, on a
per-patient basis, pooled sensitivity and specificity were 85% and 88%, respectively.
Fanti et al. [13] confirmed the good diagnostic accuracy of 11C-Cho PET or PET/CT for the detection
of BR-PCa with both pooled sensitivity and specificity equal to 89%.
As demonstrated by von Eyben et al. [12], radiolabeled Cho PET/CT detected metastatic sites in
patients with BR-PCa and PSA levels > 1 ng/mL at a clinically relevant level, without a significant
impact of types of Cho radiotracers (11C-Cho or 18F-Cho) and different acquisition protocols on the
detection rate.
Evangelista et al. [10] reported that radiolabeled Cho PET/CT has a moderate accuracy for the
detection of metastatic lymph nodes in PCa patients who are candidates for salvage lymph node
dissection (sensitivity on a patient-based and lesion-based analysis were 85% and 56%, respectively).
Recently, Kim et al. [2] demonstrated that 18F-Cho PET/CT has a low sensitivity (57%) and high
specificity (94%) for the detection of metastatic lymph nodes in patients with newly diagnosed PCa.
Treglia and colleagues [16] showed a strong relationship between PSA kinetics and the detection
rate of radiolabeled Cho PET/CT in BR-PCa. The pooled DR of radiolabeled Cho PET/CT increased
when PSA doubling time was ≤ 6 months and when PSA velocity was >1 ng/mL/year, respectively.
Therefore, PSA kinetics should be taken into account in the selection of BR-PCa patients who should
undergo radiolabeled Cho PET/CT for restaging purpose. At the same time, in another meta-analysis [9]
trigger PSA was found as an important risk factor for positive findings of Cho PET/CT: the detection
rate of Cho PET/CT for BR-PCa (59%) increased in parallel with rises in PSA values. For trigger
PSA > 2 ng/mL the detection rate of 11C-Cho PET/CT and 18F-Cho PET/CT were 73% and 83%,
respectively; the same values were 18% and 39%, respectively, when the trigger PSA was <1 ng/mL.
Beyond the diagnostic performance, radiolabeled Cho PET/CT performed for staging or restaging
of PCa led to a change in treatment management in 41% of PCa patients [17].
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Table 1. Meta-analyses on radiolabeled choline PET/CT in prostate cancer.
Authors Year Articles Patients Topic PooledSensitivity
Pooled
Specificity Pooled LR+ Pooled LR− Pooled DOR Pooled DR
Kim et al. [2] 2019 7 627 Staging 0.57 0.94 10.2 0.46 22 NA
Treglia et al. [3] 2019 5 257 Restaging NA NA NA NA NA 0.56
Zhou et al. [4] 2019 11 NA Detection of bonemetastases 0.87 0.99 NA NA 504 NA
Lin et al. [6] 2019 16 2122 Staging/restaging 0.93 0.83 4.98 0.10 68.27 NA
Sathianathen et al. [8] 2019 16 NA Restaging 0.81 0.84 5.4 0.24 25.2 0.62
Guo et al. [7] 2018 14 NA Detection of bonemetastases 0.89 0.98 40.4 0.12 344 NA
Wei et al. [9] 2018 44 NA Restaging 0.82 0.92 6.61 0.20 38.55 0.59
Evangelista et al. [10] 2016 9 NA Restaging 0.85 0.33 1.21 0.46 2.83 NA
Liu et al. [11] 2016 46 NA Staging/restaging 0.76–0.83 0.82–0.93 4.5–11.7 0.21–0.26 22–46 NA
Von Eyben et al. [12] 2016 18 2219 Restaging NA NA NA NA NA 0.55
Fanti et al. [13] 2016 18 2126 Restaging 0.89 0.89 NA NA NA 0.62
Ouyang et al. [14] 2016 46 NA Staging 0.73–0.78 0.79–0.90 NA NA NA NA
Shen et al. [15] 2014 9 NA Detection of bonemetastases 0.91 0.99 NA NA 150.70 NA
Treglia et al. [16] 2014 14 NA Restaging NA NA NA NA NA 0.58
von Eyben et al. [17] 2014 47 3167 Staging/restaging 0.59 0.92 6.86 0.45 19.17 NA
Umbehr et al. [18] 2013 29 1843 Staging/restaging 0.84/0.85 0.79/0.88 4.02/7.06 0.2/0.17 20.4/41.4 NA
Evangelista et al. [19] 2013 19 1555 Restaging 0.86 0.93 NA NA 62.12 NA
Evangelista et al. [20] 2013 10 441 Staging 0.49 0.95 8.35 0.55 18.99 NA
Legend: NA = not available; LR+ = positive likelihood ratio; LR- = negative likelihood ratio; DOR = diagnostic odds ratio; DR = detection rate.
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Table 2. Meta-analyses on PET/CT with PSMA-targeted agents in prostate cancer.
Authors Year Articles Patients Topic PooledSensitivity
Pooled
Specificity Pooled LR+ Pooled LR− Pooled DOR Pooled DR
Tan et al. [32] 2020 38 3217 Restaging NA NA NA NA NA NA (*)
Kimura et al. [21] 2020 9 NA Restaging 0.84 0.97 30.3 0.16 189 NA
Wu et al. [23] 2020 13 1597 Staging 0.65 0.94 10.6 0.37 29 NA
Perera et al. [24] 2020 37 4790 Staging/restaging 0.77 0.97 NA NA NA NA
Tan et al. [31] 2019 43 5113 Restaging NA NA NA NA NA 0.70
Treglia et al. [3] 2019 5 257 Restaging NA NA NA NA NA 0.78
Zhou et al. [4] 2019 6 NA Detection of bonemetastases 0.97 1.00 NA NA NA NA
Treglia et al. [22] 2019 6 645 Restaging NA NA NA NA NA 0.81
Lin et al. [6] 2019 13 652 Staging/restaging 0.92 0.94 7.91 0.14 79.04 NA
Pereira Mestre et al. [25] 2019 8 NA Restaging NA NA NA NA NA 0.72
Hope et al. [26] 2019 29 NA Staging/restaging 0.74/0.99 0.96/0.76 NA NA NA NA
Kim et al. [27] 2019 6 298 Staging 0.71 0.95 15.6 0.30 51 NA
Han et al. [28] 2018 15 1163 Impact onmanagement NA NA NA NA NA NA
Von Eyben et al. [29] 2018 15 1256 Staging/restaging 0.61–0.7/0.87–0.93 0.84–0.97/0.93–1 NA NA NA 0.74/0.81
Perera et al. [30] 2016 16 1309 Staging/restaging 0.86 0.86 NA NA NA 0.40/0.76
Legend: NA = not available; LR+ = positive likelihood ratio; LR− = negative likelihood ratio; DOR = diagnostic odds ratio; DR = detection rate; (*) = only available for PSA < 2 ng/mL.
Table 3. Meta-analyses on radiolabeled fluciclovine (FACBC) PET/CT in prostate cancer.
Authors Year Articles Patients Topic PooledSensitivity
Pooled
Specificity Pooled LR+ Pooled LR− Pooled DOR Pooled DR
Tan et al. [32] 2020 6 482 Restaging NA NA NA NA NA NA (*)
Bin et al. [33] 2020 9 363 Staging/restaging 0.88 0.73 3.3 0.17 20 NA
Laudicella et al. [34] 2019 9 NA Staging/restaging 0.86 0.76 4.5 0.34 16.4 NA
Kim et al. [35] 2019 13 563 Staging/restaging 0.56–0.87/0.79 0.84–0.98/0.69 5.3–19.3/2.5 0.16–0.48/0.3 34–44/9 NA
Sathianathen et al. [8] 2019 5 NA Restaging 0.80 0.62 2.1 0.36 8 0.59
Ren et al. [36] 2016 6 251 Restaging 0.87 0.66 NA NA NA NA
Legend: NA = not available; LR+ = positive likelihood ratio; LR− = negative likelihood ratio; DOR = diagnostic odds ratio; DR = detection rate; (*) = only available for PSA < 2 ng/mL
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Table 4. Meta-analyses on radiolabeled acetate PET/CT in prostate cancer.
Authors Year Articles Patients Topic PooledSensitivity
Pooled
Specificity Pooled LR+ Pooled LR− Pooled DOR Pooled DR
Liu et al. [11] 2016 5 NA Staging/restaging 0.79 0.59 1.90 0.35 6 NA
Ouyang et al. [14] 2016 5 NA Staging 0.79 0.59 NA NA NA NA
Mohsen et al. [38] 2013 23 NA Staging/restaging 0.75/0.64 0.76/0.93 1.8 0.45 3.9 NA
Legend: NA = not available; LR+ = positive likelihood ratio; LR− = negative likelihood ratio; DOR = diagnostic odds ratio; DR = detection rate.
Table 5. Meta-analyses on fluoride PET/CT in prostate cancer.
Authors Year Articles Patients Topic PooledSensitivity
Pooled
Specificity Pooled LR+ Pooled LR− Pooled DOR Pooled DR
Zhou et al. [4] 2019 7 NA Detection of bonemetastases 0.96 0.97 NA NA 674 NA
Sheikhbahaei et al. [37] 2019 12 507 Detection of bonemetastases 0.98 0.90 6.6 0.07 123.2 NA
Legend: NA = not available; LR+ = positive likelihood ratio; LR− = negative likelihood ratio; DOR = diagnostic odds ratio; DR = detection rate.
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According to the meta-analysis by Guo et al. [7], pooled sensitivity and specificity of radiolabeled
Cho PET/CT in the detection of bone metastases from PCa were 89% and 98%, respectively, on a
per-patient based analysis; on a per-lesion basis, the pooled sensitivity and specificity were 91% and
97%, respectively. Shen et al. [15] found higher diagnostic accuracy values for radiolabeled Cho PET/CT
and MR compared to bone scintigraphy. To this regard, discordant findings between radiolabeled
Cho PET/CT and bone scanning in detecting bone metastases in PCa patients are not negligible [41].
Zhou et al. [4] also demonstrated the superiority of radiolabeled Cho PET/CT compared to bone
scintigraphy in this setting; however, radiolabeled Cho PET/CT showed a slightly lower diagnostic
accuracy compared to PET/CT with PSMA-targeted agents and 18F-NaF for detecting bone metastases
of PCa.
Overall, when compared to other PET tracers for restaging of PCa [3,6,8,11,14], no statistically
significant differences were reported comparing radiolabeled Cho PET to PET with PSMA-targeted
agents or 18F-FACBC, even if a superiority of PET with PSMA-targeted agents was demonstrated in
detecting PCa lesions at low PSA levels (≤1 ng/mL). On the other hand, a higher diagnostic accuracy of
radiolabeled Cho PET compared to 11C-acetate PET and 18F-FDG PET was reported.
3.2. PET/CT with PSMA-Targeted Agents
In the first meta-analysis by Perera et al. [30], trigger PSA predicted the risk of positive PET with
68Ga-PSMA-targeted agents in patients with BR-PCa. Pooled data indicated favorable sensitivity (86%
on a per-patient basis and 80% on a per-lesion basis) and specificity (86% on a per-patient basis and
97% on a per-lesion basis) of this imaging method. Interestingly, PET/CT with 68Ga-PSMA-targeted
agents showed clinical relevance to detect sites of recurrence in PCa patients after radical prostatectomy
with PSA levels lower than 1.0 ng/mL [29]. According to an updated meta-analysis [24], PET with
68Ga-PSMA-targeted agents improved the detection of metastases in BR-PCa, and the detection rate was
related to serum PSA values: for PSA level categories ≥ 2, 1–1.99, 0.5–0.99, 0.2–0.49, and 0–0.19 ng/mL,
the percentages of positive PET/CT with 68Ga-PSMA-targeted agents were 95%, 75%, 59%, 45%,
and 33%, respectively. Tan et al. [31] reported that for PSA categories less than 0.5, 0.5 to 0.9, 1 to
1.9, and 2 ng/mL or greater the pooled detection rates of PET/CT with 68Ga-PSMA-targeted agents
were 44.9%, 61.3%, 78.2%, and 93.9%, respectively. In the meta-analysis by Hope et al. [26] using
histopathology a gold standard, the detection rate of PET/CT with 68Ga-PSMA-targeted agents was
63% in BR-PCa patients with a PSA less than 2.0 ng/mL and 94% in BR-PCa patients with a PSA
greater than 2.0 ng/mL. Notably, shorter PSA kinetics may be a predictor of positivity of PET with
PSMA-targeted agents in patients with BR-PCa [25].
According to the meta-analysis of Kimura et al. [21], PET/CT with PSMA-targeted agents performed
before salvage node dissection in BR-PCa yielded high sensitivity and specificity. The pooled sensitivity
using lesion-based and field-based analyses were 84% and 82%, respectively. The pooled specificity
using lesion-based and field-based analyses were 97% and 95%, respectively.
In a recent meta-analysis [22], PET/CT with 18F-PSMA-targeted agents showed a good detection
rate in BR-PCa. The detection rate of PET/CT with 18F-PSMA-targeted agents was influenced by
serum PSA with lower values in PCa patients with PSA < 0.5 ng/mL (49%) compared to those with
PSA ≥ 0.5 ng/mL (86%).
In a head-to-head comparative meta-analysis [3], PET/CT with PSMA-targeted agents was superior
in detecting PCa lesions only at low PSA levels (≤1 ng/mL) when compared to radiolabeled Cho
PET/CT in BR-PCa; for PSA ≤ 1 ng/mL, the detection rate of PET/CT with radiolabeled Cho and
PSMA-targeted agents were 27% and 54%, respectively. Conversely, in BR-PCa patients with PSA
> 1 ng/mL, a statistically significant difference in detection rate among these two methods has not
been reported by evidence-based manuscripts [3,6]. In a comparative analysis among PET/CT with
PSMA-targeted agents and 18F-FACBC in BR-PCa with PSA levels < 2 ng/mL [32], PET/CT with
PSMA-targeted agents had a significantly higher detection rate (80%) compared to PET/CT with
18F-FACBC (62%) for PSA levels of 1.0–1.9 ng/mL.
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In a meta-analysis about the staging setting, PET/CT with PSMA-targeted agents showed a
moderate sensitivity (71%) and high specificity (95%) for the detection of metastatic lymph nodes in
patients with newly diagnosed intermediate to high-risk PCa [27]. In another meta-analysis using
pathology as a gold standard [26], PET/CT with 68Ga-PSMA-targeted agents at initial PCa staging
demonstrated a sensitivity and specificity of 74% and 96%, respectively. In staging intermediate to
high-risk PCa, PET/CT with 68Ga-PSMA-targeted agents had a higher sensitivity compared to MR
(65% versus 41%, respectively) and similar specificity (94% versus 92%, respectively) in detecting
lymph nodal metastases [23].
Compared to other PET methods, PET/CT with PSMA-targeted agents had the highest
patient-based sensitivity (97%) and specificity (100%) in detecting bone metastases [4].
According to the meta-analysis of Han et al. [28] focused on the impact of PET/CT with
68Ga-PSMA-targeted agents in PCa patients, this imaging method altered the management in about
half of PCa patients.
3.3. 18F-FACBC (fluciclovine) PET/CT
In some meta-analyses, diagnostic accuracy of 18F-FACBC PET/CT was reported as moderate:
higher in the staging than restaging setting [8,32–36]. In the first meta-analysis by Ren et al. [36],
18F-FACBC PET/CT demonstrated a pooled sensitivity and pooled specificity of 87% and 66%,
respectively, in detecting BR-PCa. In another study, 18F-FACBC PET/CT had lower accuracy values
than radiolabeled Cho PET in a restaging setting: the pooled sensitivity was similar (80.9% for
radiolabeled Cho PET/CT and 79.7% for 18F-FACBC PET/CT, respectively), but the pooled specificity
was higher for radiolabeled Cho PET/CT (84.1%) compared to 18F-FACBC PET/CT (61.9%) [8]. In a
comparative analysis among PET/CT with 18F-FACBC and PSMA-targeted agents in BR-PCa with PSA
levels < 2 ng/mL [32], pooled detection rates for PET/CT with 18F-FACBC were 37% for a PSA level
less than 0.5 ng/mL, 48% for a PSA level of 0.5–0.9 ng/mL, and 62% for a PSA level of 1.0–1.9 ng/mL,
with significant lower detection rate of 18F-FACBC PET/CT compared to PET/CT with PSMA-targeted
agents in the last subgroup of patients.
Based on the meta-analysis by Kim et al. [35], the pooled sensitivity for 18F-FACBC PET or PET/CT
for diagnosis of primary PCa was 87% and the pooled specificity 84%. For lymph nodal staging,
the pooled sensitivity was 56% and the pooled specificity was 98%. For detection of BR-PCa, the
pooled sensitivity was 79% and the pooled specificity was 69%.
Another two recent meta-analyses [33,34] confirmed the good sensitivity (86–88%) and moderate
specificity (73–76%) of 18F-FACBC PET/CT in staging and restaging PCa.
3.4. 11C-Acetate PET/CT
11C-acetate PET/CT showed intermediate or low diagnostic accuracy values in PCa according
to available meta-analyses, both in staging and restaging settings [11,14,38]. According to the
meta-analysis of Mohsen et al. [38], for the evaluation of primary tumors, 11C-acetate PET showed
moderate pooled sensitivity (75.1%) and specificity (75.8%) [38]. For detection of recurrence, pooled
sensitivity was 64% and pooled specificity was 93%. Sensitivity for recurrence detection was higher in
PCa patients with serum PSA values at relapse > 1 ng/mL [38].
Overall, compared to radiolabeled Cho PET/CT, 11C-acetate PET/CT seems to have similar
sensitivity in localizing sites of relapse in BR-PCa. The complete lack of urinary excretion of 11C-acetate
offers a distinct advantage over radiolabeled Cho in image interpretation [42,43].
3.5. 18F-NaF (Fluoride) PET/CT
Two meta-analyses showed high-accuracy values of 18F-NaF PET/CT in the detection of bone
metastases of patients with PCa [4,37]. Sheikhbahaei et al. reported a pooled sensitivity and specificity
of 98% and 90%, respectively, with better overall accuracy of 18F-NaF PET/CT compared to bone
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scintigraphy and MR [37]. Even if PET/CT with the other radiotracers mentioned above is also able to
detect bone metastases, potentially with even greater sensitivity than 18F-NaF PET/CT (e.g., PET/CT
with PSMA-targeted agents may detect lesions in bone marrow even before associated lesions of the
bone matrix), the use of 18F-NaF PET/CT in the detection of bone metastases in PCa generally represents
a clinical application in patients with far more advanced disease than biochemical recurrence [4,37].
3.6. 18F-FDG PET/CT
As demonstrated by some evidence-based articles, 18F-FDG PET/CT showed lower accuracy
values than other PET tracers in detecting PCa [11,14].
In a meta-analysis by Bertagna et al. [39], prostate incidental uptake was observed in about 2%
of 18F-FDG PET/CT scans performed in male patients. The pooled risk of malignancy verified by
biopsy was about 60%. Peripheric site but not presence or absence of calcification was a predictor of
malignancy. Therefore, whenever an incidental 18F-FDG uptake is detected in the prostate, further
investigation should be warranted to exclude malignancy, in particular when located in the peripheric
site of the prostate gland [39].
3.7. PET/MR with Different Radiotracers
A meta-analysis evaluated the accuracy of hybrid PET/MR imaging in PCa by using different
radiopharmaceuticals, showing higher sensitivity of PET/MR compared to multiparametric MR
for the diagnosis of primary PCa [5]. Another recent meta-analysis focused on PET/MR with
68Ga-PSMA-targeted agents [40] found that this method is likely effective in the diagnosis of primary
PCa, and its diagnostic accuracy BR-PCa was positively correlated to serum PSA levels: The pooled
sensitivity and specificity in detecting primary PCa were 83% and 81%, respectively; in BR-PCa,
the pooled detection rate was 76%. For PSA level categories 0−0.2 ng/mL, 0.2−1 ng/mL, 1−2 ng/mL,
and more than 2 ng/mL, the pooled detection rates were 38%, 67%, 74%, and 95%, respectively.
Notably, current combined PET/MR cameras do not employ state-of-the-art detectors and
reconstruction technologies that would be typically present in current clinical PET/CT scanners,
where the resulting improvements in resolution and sensitivity are clearly relevant to the problem of
finding small lesions.
4. Discussion
To date, several meta-analyses reported data about the diagnostic performance of PET imaging
in PCa with different radiotracers [2–40]. Since the first evidence-based papers were published,
radiolabeled Cho PET/CT showed high diagnostic accuracy in a restaging setting of patients with
BR-PCa [13,19], particularly for the detection of locoregional and distant metastases. Subsequently,
the choice between the 18F or 11C-Cho radiotracers and different acquisition protocols showed no
significant impact on diagnostic accuracy [12], being useful for several clinical purposes, such as the
guide of salvage lymph node dissection [10]. Nevertheless, PSA value quickly emerged as a critical
aspect in patients eligible for radiolabeled Cho PET/CT, since this method showed higher detection
rate for trigger PSA > 2 ng/mL [9,16]. According to those evidences, radiolabeled Cho PET/CT is
widely used in the daily routine for the restaging of BR-PCa in patients with intermediate and high
PSA values [1].
At the same time, the use of radiolabeled Cho for staging purpose before first-line treatment is still
debated. Firstly, Cho PET/CT provided low sensitivity but high specificity in the detection of lymph
node metastases [2,20]. Conversely, other studies found good overall accuracy of Cho PET/CT in this
setting [17], and also when compared to other functional and morphological imaging tools [11,14].
The best diagnostic performance of Cho PET/CT for staging purpose was shown for the detection
of bone metastases [7,15]. For these reasons, radiolabeled Cho is not extensively used for staging
purposes in PCa patients: more evidences are needed in order to promote the routine use of Cho PET
in this setting [1].
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More recently, PSMA-targeted radiotracers emerged in order to overcome the limitations of Cho
PET in the diagnosis of early recurrence of PCa. Indeed, several studies showed high diagnostic
accuracy of PET/CT with PSMA-targeted agents in PCa both for restaging and staging purpose. One of
the advantages of receptor-based radiopharmaceuticals, such as PSMA-targeted agents, compared to
metabolic tracers (i.e., radiolabeled Cho or FACBC) is the higher target-to-background ratio resulting in
higher sensitivity and inter-reader agreement [44]. Since the first published meta-analyses, compared to
radiolabeled Cho PET/CT, PET/CT with 68Ga-PSMA-targeted agents showed a higher detection rate in a
restaging setting in patients with serum PSA levels < 1.0 ng/mL [22,24,25,30,31]. Using histopathology
as the gold standard, the detection rate of PET/CT with 68Ga-PSMA-targeted agents was 63% in
BR-PCa patients with a PSA < 2 ng/mL and 94% in BR-PCa patients with a PSA > 2.0 ng/mL [26].
Moreover, PET/CT with 18F-PSMA-targeted agents recently showed a good detection rate in a restaging
setting: the pooled DR was 86% for PSA ≥ 0.5 ng/mL and 49% for PSA < 0.5 ng/mL [22]. Furthermore,
PET/CT with PSMA-targeted agents showed good accuracy values in some meta-analyses about
staging setting before first-line treatment [6,23,26,27], with particular regard to bone metastases [4].
All the meta-analyses here discussed showed an increasing interest about the role of PET/CT with
PSMA-targeted agents due to their good diagnostic performance in several clinical settings of PCa [1].
PSMA-targeted agents are also an excellent theragnostic agent allowing the detection of PCa lesions
by PET/CT imaging and, subsequently, the irradiation of metastatic sites with beta or alpha particle
emitters [44]. Despite these clear evidences, PSMA-targeted agents are still classified as experimental
radiopharmaceuticals in several countries at the moment, and this has an influence on the use of these
PET radiopharmaceuticals in the clinical practice.
Finally, less evidence-based data are available about other PET radiopharmaceuticals. 18F-FDG
PET/CT could show incidental radiopharmaceutical uptake in the prostate addressing further
investigation [39], but low accuracy values emerged in staging PCa [11,14]. 11C-acetate PET/CT
showed intermediate or low-accuracy values both in PCa staging and restaging setting [11,14,38].
18F-FACBC PET/CT showed good accuracy values, with better performance in the staging than in
restaging setting [8,32–36]. High accuracy values of 18F-NaF PET/CT emerged in the detection of bone
metastases of patients with PCa [4,37]. Few evidence-based data were found for hybrid PET/MR with
different radiotracers [5,40].
Some limitations of PET imaging with different radiopharmaceuticals should be briefly discussed.
In particular, the detection rate of PCa lesions with the several PET radiopharmaceuticals described
seems to be strictly related to serum PSA values and PSA kinetics. Therefore, false negative
cases are more common in PCa patients with lower PSA serum values or slower PSA kinetics.
Moreover, false positive findings due to radiopharmaceutical uptake in other tumors or benign
conditions should be taken into account [45].
Some limitations of the selected meta-analyses should be discussed too, because they could
hamper the achievement of definitive conclusions on the diagnostic performance of PET with several
radiopharmaceuticals in PCa. First of all, in some meta-analyses a limited number of articles were
included, thus reducing the statistical power of the analysis. In several meta-analyses, a significant
statistical heterogeneity among the included studies in terms of diagnostic accuracy outcomes has been
identified. This heterogeneity may be explained, for instance, by differences between the characteristics
of PCa patients, methodological aspects, quality of the studies, and PET interpretation criteria [46,47].
Many of the studies included in the selected meta-analyses are single-center and retrospective series,
limiting their applicability to a broader setting. The lack of a reliable “gold standard” as histopathology
for the diagnosis of PCa in some articles could be another limitation of the described meta-analyses
(verification bias), causing a possible overestimation of diagnostic test performance. Lastly, reporting
bias (such as publication bias when studies reporting significant findings are more likely to be published
than those reporting nonsignificant results) cannot be excluded in some selected meta-analyses [46,47].
Our review was focused on collecting data about the diagnostic performance only. We have to
underline that diagnostic performance is not a measure of clinical effectiveness, and good diagnostic
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accuracy of an imaging method does not necessarily result in improved patient outcomes. Therefore,
other factors beyond the diagnostic performance should influence the choice of an imaging modality
in patients with PCa both at staging and restaging (e.g., availability, safety, legal, organization and
economic aspects, and cost-effectiveness). Therefore, recommendations on the use of PET/CT or
PET/MR with different radiopharmaceuticals in PCa should not be provided, taking into account only
information on the diagnostic performance [48].
According to recent international guidelines, when conventional imaging is negative or
equivocal in PCa patients with a high risk of metastatic disease, PET/CT or PET/MRI with different
radiopharmaceuticals may add clinical benefit, although prospective data are limited [1]. In restaging
PCa patients with negative conventional imaging for men for whom salvage therapy is contemplated,
PET/CT or PET/MRI with different radiopharmaceuticals (including PSMA-targeted agents or
radiolabeled Cho or 18F-FACBC or 18F-NaF) is recommended as they have superior disease detection
performance characteristics and may alter patient management [1].
Overall, based on current evidence-based data, we would like to recommend more prospective
multicentric studies and cost-effectiveness analyses for all PET tracers in order to clarify and strengthen
their use in the clinical practice.
5. Conclusions
Evidence-based data showed the good diagnostic performance of PET imaging with several
radiopharmaceuticals in different PCa clinical settings, including staging and restaging. In BR-PCa
patients with low serum PSA values, PET with PSMA-targeted agents seems to provide a higher
detection rate compared to PET with other radiopharmaceuticals. More prospective multicentric
studies and cost-effectiveness analyses are warranted.
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